The New York-based AI biotech will use its AMICA-OS platform to analyze clinical immune data for BMS, aiming to inform patient stratification, biomarkers, and trial decisions.
The modern social calendar is often at odds with our biological requirements. Whether it is a holiday season, a string of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback